DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarte…
Author: Business Wire
US Eye Partners with Prominent Virginia Optometric Physician
VIRGINIA BEACH, Va.–(BUSINESS WIRE)– #Eyecare–US Eye Partners with Prominent Virginia Optometric Physician, Dr. Kenneth Lebow
Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today reported recent corporate highlights and financial resu…
NovaBay Pharmaceuticals to Hold First Quarter 2022 Conference Call on May 12
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2022 after market close on Thursday, May 12, 2022 and will hold an investment …
Glaucoma Epidemiology Forecast Report 2021-2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Glaucoma – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye’s optic nerve, resulting in progr…
Glaukos Corporation Announces First Quarter 2022 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced finan…
STAAR Surgical Reports Record First Quarter Net Sales of $63.2 Million Up 25% Y/Y
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the first quarter ended A…
Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Kelly Mizer, Aldeyra’s Vice President, C…
Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results
PARSIPPANY, N.J.–(BUSINESS WIRE)–Iveric Bio announced financial and operating results for the first quarter ended Mar. 31, 2022 and provided a general business update.
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced two scientific…
Resumen: Horizon Therapeutics plc recibe la aprobación para UPLIZNA® (inebilizumab) por parte de la Comisión Europea (CE) para el tratamiento de adultos con trastorno del espectro de la neuromielitis óptica (NMOSD)
DUBLÍN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) ha anunciado hoy la aprobación por parte de la Comisión Europea (CE) de UPLIZNA® (inebilizumab) como monoterapia para el tratamiento de pacientes adultos con trastorno del espectro de la …
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
United States Ophthalmic Compounding Pharmacies Industry Report to 2028 – Players Profiled Include Nora Apothecary, Lifecare Pharmacy, Avella Specialty Pharmacy and Triangle Compounding Pharmacy – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “U.S. Ophthalmic Compounding Pharmacies Market, by Drug, by Formulation, by Therapeutic Application, and by Pharmacy Type – Size, Share, Outlook, and Opportunity Analysis, 2021 – 2028” report has been added to ResearchAndMa…
Samenvatting: Horizon Therapeutics plc ontvangt goedkeuring van de Europese Commissie (EC) voor UPLIZNA® (inebilizumab) voor de behandeling van volwassenen met neuromyelitis Optica Spectrum Disorder (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) heeft vandaag de goedkeuring aangekondigd van de Europese Commissie (EC) van UPLIZNA® (inebilizumab) als monotherapie voor de behandeling van volwassen patiënten met neuromyelitis optica …
Warby Parker to Announce First Quarter 2022 Financial Results on May 16, 2022
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the first quarter of 2022 will be released before market open on M…
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced new preclinic…
Voxeleron Launches iNebula™, a Cloud-Based Platform for Optimized Ophthalmic Clinical Trial Workflow
SAN FRANCISCO–(BUSINESS WIRE)–Voxeleron, a cloud-based platform provider that analyzes and tracks all formats of ophthalmic data, today announced the availability of iNebula, a digital media platform specifically developed to optimize ophthalmic clin…
Ingenia Therapeutics & Mosaic Biosciences Present Preclinical Data on the Variants of the Bispecific Antibody IGT-427 for the Treatment of Degenerative Retinal Diseases
CAMBRIDGE, Mass. & BOULDER, Colo.–(BUSINESS WIRE)–Ingenia Therapeutics and Mosaic Biosciences today announced the presentation of new data on pharmacokinetically-enhanced variants of IGT-427, Ingenia’s bispecific antibody that potently blocks VEGF an…
LENSAR to Report First Quarter 2022 Financial Results on Monday, May 9, 2022
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fir…
Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States
EMERYVILLE, Calif.–(BUSINESS WIRE)–Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today announced that Verkazia® (cyclosporine ophthalmic emulsion) 0.1% is …